AgomAb Therapeutics (NASDAQ:AGMB) Director Buys 5,000 Shares of Stock

Key Points

• Director David Epstein bought 5,000 AGMB shares at an average price of $8.90, investing $44,500 and increasing his holdings by 50% to 15,000 shares.
• AgomAb shares rose 1.3% to $9.34, but remain well below their 52-week high of $17.82. The company reported a quarterly loss of $0.46 per share, with analysts expecting a full-year loss of $1.76 per share.
• Analyst sentiment is broadly positive, with seven Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $37.50; published targets include $34 and $60.

AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein bought 5,000 shares of the company's stock in a transaction that occurred on Thursday, October 8th. The shares were bought at an average price of $8.90 per share, for a total transaction of $44,500.00. Following the completion of the acquisition, the director owned 15,000 shares in the company, valued at approximately $133,500. This trade represents a 50.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

AgomAb Therapeutics Stock Up 1.3%

NASDAQ:AGMB traded up $0.12 during trading hours on Friday, hitting $9.34. The stock had a trading volume of 34,701 shares, compared to its average volume of 139,883. AgomAb Therapeutics NV has a 1-year low of $7.97 and a 1-year high of $17.82. The business has a 50 day simple moving average of $12.68 and a two-hundred day simple moving average of $11.95.

AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, analysts forecast that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AGMB has been the subject of several recent research reports. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an "overweight" rating for the company. B. Riley Financial started coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a "buy" rating and a $34.00 target price for the company. HC Wainwright reiterated a "buy" rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Wall Street Zen downgraded shares of AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, September 27th. Finally, Piper Sandler began coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an "overweight" rating and a $60.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab's lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.